Lyophilisation cycle development in under 60 days
Lyophilisation and liquid form contractor LyoTechnica has launched a new contract drug development services for injectable pharmaceuticals.
The company said that the new unit will offer both analytical and formulation development as well as sterile stability batches and stability testing batch manufacturing services.
The CUS firm claims to be able to complete “typical” lyophilisation cycle development in less than sixty days, which makes the service ideal with resource limited clients according to CEO Glenn Wicks Jr.
“We work with pharmaceutical companies with limited resources as well as larger firms needing additional resources applied quickly to a project. Our framework allows for cost-effective and efficient development.”
AspenTech lands Big Pharma customers
US software firm AspenTech says deals with UK majors GlaxoSmithKline (GSK) and AstraZeneca demonstrate utility of aspenOne in pharmaceutical industry process optimisation.
The company said that its solubility modeling technology provides "Quality by Design" (QbD) capabilities that help drug manufacturers comply with the latest industry regulatory initiatives.
AspentTech cited GSK, a recent addition to its customer base, as an example of aspenOne’s drug industry utility.
It explained that GSK has been able to thoroughly understand the solubility properties of new chemical entities (NCE) to assess risks and improve confidence during the development of new pharmaceuticals.
This claim was supported by GSK’s Stephen Carino who said: "In our high-throughput screening workflow, we have utilized NRTL-SAC in Aspen Properties to predict the equilibrium solubility of the drug in single- and multi-component solvent systems.
“This rational solvent selection coupled with the systematic screening approach has allowed us to assess risk around solid forms and improve our confidence in the robustness of the API processes."
*Outsourcing-pharma hopes readers in the Southern hemisphere are enjoying the winter too.